The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?
作者信息
Barberio Brigida, Zingone Fabiana, Bertani Lorenzo, Savarino Edoardo
机构信息
Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy.
Gastroenterology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy.
出版信息
Gastroenterology. 2021 Apr;160(5):1903-1904. doi: 10.1053/j.gastro.2020.07.017. Epub 2020 Jul 17.
Abstract
摘要
相似文献
1
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?
Gastroenterology. 2021 Apr;160(5):1903-1904. doi: 10.1053/j.gastro.2020.07.017. Epub 2020 Jul 17.
2
Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
Gastroenterology. 2021 Apr;160(5):1877-1878. doi: 10.1053/j.gastro.2020.05.026. Epub 2020 May 12.
3
Safety of biologics in inflammatory bowel disease patients with COVID-19.
Int J Colorectal Dis. 2021 Sep;36(9):2051-2055. doi: 10.1007/s00384-021-03977-9. Epub 2021 Jun 15.
4
Adherence of Infusible Biologics During the Time of COVID-19 Among Patients With Inflammatory Bowel Disease: A Nationwide Veterans Affairs Cohort Study.
Gastroenterology. 2020 Oct;159(4):1592-1594.e1. doi: 10.1053/j.gastro.2020.06.044. Epub 2020 Jun 20.
5
Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment.
Gastroenterology. 2020 Dec;159(6):2229-2231.e2. doi: 10.1053/j.gastro.2020.08.046. Epub 2020 Aug 26.
6
Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2020 Sep 18;26(10):e107-e109. doi: 10.1093/ibd/izaa242.
7
Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
Aliment Pharmacol Ther. 2021 Jul;54(2):208-209. doi: 10.1111/apt.16459.
8
Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic.
Inflamm Bowel Dis. 2020 Oct 23;26(11):e137. doi: 10.1093/ibd/izaa207.
9
Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre.
Dig Liver Dis. 2020 Nov;52(11):1248-1249. doi: 10.1016/j.dld.2020.07.021. Epub 2020 Jul 27.
10
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy.
J Gastroenterol Hepatol. 2021 Nov;36(11):3050-3055. doi: 10.1111/jgh.15591. Epub 2021 Jul 5.
引用本文的文献
1
0Effects of the COVID-19 Pandemic on Treatment Adherence in Patients with Chronic Heart Failure.
Caspian J Intern Med. 2022;13(Suppl 3):199-203. doi: 10.22088/cjim.13.0.199.
2
Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak.
J Clin Med. 2021 Jul 24;10(15):3270. doi: 10.3390/jcm10153270.
Zotero 插件